It plays critical roles in folding proteins in the secretory pathway such as Toll-like receptors and integrins.

[9] Tumor-derived HSP90B1 (vitespen) has entered clinical trials for cancer immunotherapy.

[10][11][12][13] grp94 has been shown to be a target for treatment of a plethora of diseases such as glaucoma, multiple myeloma, and metastatic cancer.

grp94 includes 5 distinct amino acids in its primary sequence which creates 2 unique sub-pockets, S1 and S2.

These sub-pockets have been utilized in current research in order to inhibit the chaperone since its client proteins seem to be up-regulated in cancer cells.